

Xiaojing Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10853677/publications.pdf>

Version: 2024-02-01

16
papers

3,471
citations

623734

14
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

7262
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium. <i>Blood</i> , 2018, 131, 1145-1148.	1.4	44
2	Epigenetic landscape change analysis during human EMT sheds light on a key EMT mediator TRIM29. <i>Oncotarget</i> , 2017, 8, 98322-98335.	1.8	13
3	Isoform switching and exon skipping induced by the DNA methylation inhibitor 5-Aza-2â€²-deoxycytidine. <i>Scientific Reports</i> , 2016, 6, 24545.	3.3	15
4	DNMT3B isoforms without catalytic activity stimulate gene body methylation as accessory proteins in somatic cells. <i>Nature Communications</i> , 2016, 7, 11453.	12.8	109
5	Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer. <i>Cancer Cell</i> , 2014, 26, 577-590.	16.8	959
6	Functional DNA demethylation is accompanied by chromatin accessibility. <i>Nucleic Acids Research</i> , 2013, 41, 3973-3985.	14.5	77
7	Synergistic Re-Activation of Epigenetically Silenced Genes by Combinatorial Inhibition of DNMTs and LSD1 in Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e75136.	2.5	33
8	Gene Reactivation by 5-Aza-2â€²-Deoxycytidineâ€”Induced Demethylation Requires SRCAPâ€”Mediated H2A.Z Insertion to Establish Nucleosome Depleted Regions. <i>PLoS Genetics</i> , 2012, 8, e1002604.	3.5	52
9	DNA Methylation Screening Identifies Driver Epigenetic Events of Cancer Cell Survival. <i>Cancer Cell</i> , 2012, 21, 655-667.	16.8	240
10	DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. <i>Human Molecular Genetics</i> , 2011, 20, 4299-4310.	2.9	172
11	Targeting DNA methylation for epigenetic therapy. <i>Trends in Pharmacological Sciences</i> , 2010, 31, 536-546.	8.7	275
12	<i>miR-449a</i> and <i>miR-449b</i> are direct transcriptional targets of E2F1 and negatively regulate pRbâ€”E2F1 activity through a feedback loop by targeting <i>CDK6</i> and <i>CDC25A</i> . <i>Genes and Development</i> , 2009, 23, 2388-2393.	5.9	242
13	Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 3191-3202.	4.1	65
14	CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells. <i>PLoS ONE</i> , 2009, 4, e5011.	2.5	155
15	DACT3 Is an Epigenetic Regulator of Wnt/ β -Catenin Signaling in Colorectal Cancer and Is a Therapeutic Target of Histone Modifications. <i>Cancer Cell</i> , 2008, 13, 529-541.	16.8	216
16	Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. <i>Genes and Development</i> , 2007, 21, 1050-1063.	5.9	804